PepEvolutionPT-141
Bremelanotide / Vyleesi
The FDA-approved melanocortin agonist for low sexual desire — real registered-trial evidence, with a notable nausea and blood-pressure profile.
Verdict — B · Viable
One of the few catalog compounds with an actual FDA approval and registered phase 3 data behind it. Held to a B by a real tolerability burden — nausea, transient blood-pressure rise and a cardiovascular contraindication — plus gray-market sourcing variance. Buy verified and respect the BP contraindication.
Overview
Bremelanotide (PT-141) is a melanocortin-4 receptor agonist FDA-approved in 2019 (Vyleesi) for acquired, generalized hypoactive sexual desire disorder in premenopausal women, on the strength of the RECONNECT phase 3 program. It acts centrally rather than vascularly, distinguishing it from PDE5 inhibitors. The approved evidence is solid; the practical drawbacks are common nausea, transient blood-pressure elevation (contraindicating uncontrolled hypertension and cardiovascular disease) and focal hyperpigmentation with repeated dosing.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.